What Alkermes (ALKS) Said on Its Q3 Earnings Call

Alkermes (ALKS) expects Q4 proprietary product net sales of $400M-$420M and $1.6B for full-year 2026. Q3 GAAP net income was $16.3M, EBITDA $63M, and cash $787.6M. The company is advancing its orexin pipeline, with Phase III trials for alixorexton in narcolepsy and IH, and Phase II trials for ALKS 7290 in ADHD and depression.

Original reporting
Published Nov 3, 2026, 6:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 6:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Alkermes (ALKS) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$ALKSBullishMed
01

Why it matters

The most tradable elements are the explicit Q4 proprietary product net sales range, full-year 2026 net sales expectations for the proprietary portfolio, and the planned regulatory and clinical milestones that shape probability-weighted value for LUMRYZ and alixorexton. Cost structure commentary (COGS step-up and R&D ramp) provides a counterweight for margin expectations.

02

Market read

Provides forward-looking sales guidance and a structured timeline of clinical readouts and potential IH launch timing, which can drive biotech valuation and positioning.

03

What to watch

The article notes “somewhat marginal” initial impact from Takeda’s anticipated orexin launch, but does not quantify competitive pricing or uptake risk; investors may discount the assumption until real-world market share data emerges.

Relevance 7/10Novelty 6/10Timing: post-call, positioning ahead of mid-2027 Phase III top-line readouts

Background

This is a summary of Alkermes’ Q3 earnings call commentary, covering 2026 sales expectations, 2027 cost outlook, and clinical progress across LUMRYZ (IH/narcolepsy) and orexin/ADHD programs.

Company-level read

Ticker impact

$ALKSBullishMedium confidence
Context

Alkermes guided proprietary product net sales for Q4 ($400M-$420M) and reiterated 2026 expectations, while detailing LUMRYZ and orexin pipeline timelines.

Expected impact

Likely upward bias as investors price in LUMRYZ sales trajectory and upcoming Phase III milestones, partially offset by higher COGS and R&D spend.

Evidence & confidence

The article provides concrete forward-looking sales expectations and multiple pipeline readout dates (mid-2027, year-end/early 2027, March 2028 potential launch), which typically drive biotech risk/reward repricing. It also flags higher COGS tied to LUMRYZ inventory accounting and rising R&D, which can temper the reaction.

Market effects

Reinforces investor focus on CNS/central nervous system drug pipelines and orexin-therapy competitive dynamics, including read-through from Takeda’s anticipated orexin launch.

Limited direct regional impact; primarily US-listed biotech sentiment.

Moderate, as orexin therapy competition and Phase III timelines can influence global CNS biotech risk appetite.

Counterpoint

The call emphasizes higher near-term costs (COGS and R&D) and relies on future regulatory interactions, so the near-term earnings power may not improve as quickly as the sales guidance implies.

Key entities

  • Alkermes plc

    NASDAQ-listed biopharmaceutical company focused on CNS therapies; subject of the earnings-call summary.

  • LUMRYZ

    Alkermes’ oxybate therapy referenced for IH and narcolepsy development and supplemental NDA plans.

  • alixorexton

    Orexin 2 receptor agonist in Phase III for narcolepsy and IH, with Vibrance-3 Phase II enrollment completed.

  • ALKS 7290

    Orexin-related candidate in Phase Ib/Phase II studies for ADHD and adjunctive MDD.

  • ALKS 4510

    Planned Phase II study for fatigue associated with multiple sclerosis or Parkinson’s disease.

Related articles

$TAKHighAI 8/10

Awake to the possibilities: a ‘first in class’ narcolepsy drug could be transformational

Takeda's narcolepsy drug Orzeyful (oveporexton), approved by the FDA in 2026, targets the underlying cause of type 1 narcolepsy by activating orexin receptors. The drug, taken twice daily, shows immediate effects but has some side effects. Takeda seeks UK approval. Other companies like Eli Lilly, Alkermes, and Lundbeck are also developing orexin agonists for sleep disorders. (350 characters)

$ALKSMed

H.C. Wainwright raises Alkermes stock price target to $50 on pipeline progress

H.C. Wainwright raised its price target for Alkermes (ALKS) to $50 from $43, citing progress in its clinical pipeline and commercial revenue. The stock is up 63% year-to-date. The firm maintained a Neutral rating. Alkermes recently reported stronger-than-expected Q3 2026 results, with adjusted earnings of $0.09 per share and revenue of $480.1 million. Baird and Wells Fargo also raised their price targets.

$ALKSMed

Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31%

Alkermes PLC (ALKS) reported a 31% surge in proprietary sales for Q3 2026, but R&D and SG&A expenses rose due to the Avadel acquisition and expanded orexin development. LYBALVI's gross-to-net adjustments are expected to reach 45% in 2027, potentially pressuring net sales growth. The company faces competition from Takeda's oveporexton in the narcolepsy market. Alkermes expects to provide full 2027 financial guidance in February, leaving investors with uncertainty.

$ALKSHighAI 8/10

Alkermes (ALKS) Q3 2026 Earnings Call Transcript

Alkermes (ALKS) reported Q3 2026 net sales of $417.3M, up 31% YoY. Key products include VIVITROL ($127.6M), ARISTADA ($103.9M), LYBALVI ($95.9M), and LUMRYZ ($89.9M). Full-year guidance remains unchanged. The company expects continued growth in 2027 and beyond, driven by expanded payer access and new product launches.